Immune Oncology Research Institute Highlights KEYNOTE-689 Results in Head and Neck Cancer
Immune Oncology Research Institute/ LinkedIn

Immune Oncology Research Institute Highlights KEYNOTE-689 Results in Head and Neck Cancer

Immune Oncology Research Institute shared on LinkedIn:

“A Major Breakthrough in Head and Neck Cancer Treatment: Immunotherapy Significantly Improves Outcomes!

The phase III KEYNOTE-689 trial, published in The England Journal of Medicine in June 2025, provides compelling evidence supporting perioperative pembrolizumab in patients with locally advanced head and neck squamous-cell carcinoma (HNSCC).

Led by Dr. Ravindra Uppaluri and Dr. Robert I. Haddad, alongside international investigators, the study enrolled 714 patients. At 36 months, event-free survival among patients with PD-L1 CPS ≥10 reached 59.8% with pembrolizumab versus 45.9% with standard care alone, representing a 34% relative reduction in the hazard of progression, recurrence, or death.

Beyond its efficacy, the KEYNOTE-689 trial offers important insights into the safety and feasibility of integrating immunotherapy into surgical cancer treatment.

Perioperative pembrolizumab improved event-free survival without compromising surgical completion rates. Grade ≥3 treatment-related adverse events occurred in 44.6% of patients receiving pembrolizumab compared with 42.9% in the control group, with no new safety signals identified.

These findings support the potential of perioperative immunotherapy in curative-intent treatment strategies, particularly for patients with PD-L1–expressing tumors.”

Title: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Authors: Ravindra Uppaluri, Robert I. Haddad, Yungan Tao, Christophe Le Tourneau, Nancy Y. Lee, William Westra, Rebecca Chernock, Makoto Tahara, Kevin J. Harrington, Arkadiy L. Klochikhin, Irene Braña, Gustavo Vasconcelos Alves, Brett G. M. Hughes, Marc Oliva, Iane Pinto Figueiredo Lima, Tsutomu Ueda, Tomasz Rutkowski, Ursula Schroeder, Paul-Stefan Mauz, Thorsten Fuereder, Simon Laban, Nobuhiko Oridate, Aron Popovtzer, Nicolas Mach, Yevhen Korobko, Diogo Alpuim Costa, Anupama Hooda-Nehra, Cristina P. Rodriguez, R. Bryan Bell, Cole Manschot, Kimberly Benjamin, Burak Gumuscu, Douglas Adkins

Read the full study.

You can also read:

Immune Oncology Research Institute Highlights KEYNOTE-689 Results in Head and Neck Cancer